Search Results - "Norris, Leann B"

Colony-Stimulating Factors for Febrile Neutropenia during Cancer Therapy by Bennett, Charles L, Djulbegovic, Benjamin, Norris, LeAnn B, Armitage, James O

“…A woman receives a diagnosis of diffuse large B-cell lymphoma; a standard chemotherapy regimen is recommended. Use of prophylactic granulocyte CSF is…”
Get full text

Systematic review of antimicrobial lock therapy for prevention of central-line-associated bloodstream infections in adult and pediatric cancer patients by Norris, LeAnn B., Kablaoui, Farah, Brilhart, Maggie K., Bookstaver, P. Brandon

“…•Cancer patients require prolonged venous access, leading to bacteremia.•Antibiotic lock therapy (ALT) has been shown to be effective in reducing…”
Get full text

Generic oncology drugs: are they all safe? by Yang, Y Tony, ScD, Nagai, Sumimasa, MD, Chen, Brian K, PhD, Qureshi, Zaina P, PhD, Lebby, Akida A, BA, Kessler, Samuel, BA, Georgantopoulos, Peter, MPH, Raisch, Dennis W, Prof, Sartor, Oliver, Prof, Hermanson, Terhi, MD, Kane, Robert C, MD, Hrushesky, William J, Prof, Riente, Joshua J, PharmD, Norris, LeAnn B, PharmD, Bobolts, Laura R, PharmD, Armitage, James O, Prof, Bennett, Charles L, Prof

“…Summary Although the availability of generic oncology drugs allows access to contemporary care and reduces costs, there is international variability in the…”
Get full text

Pharmacists' roles in oncology pharmacy services: Results of a global survey by Holle, Lisa M, Harris, Christy S, Chan, Alexandre, Fahrenbruch, Rebecca J, Labdi, Bonnie A, Mohs, Jocelyn E, Norris, Leann B, Perkins, Janelle, Vela, Cory M

“…Background Oncology pharmacists are capable of providing medication therapy management (MTM) because of their level of training, practice experiences, and…”
Get full text

Major hemorrhage in chronic lymphocytic leukemia patients in the US Veterans Health Administration system in the pre‐ibrutinib era: Incidence and risk factors by Georgantopoulos, Peter, Yang, Huiying, Norris, LeAnn B., Bennett, Charles L.

“…Chronic lymphocytic leukemia (CLL) patients are at increased risk for major hemorrhage (MH). We examined incidence of and risk factors for MH in CLL patients…”
Get full text

Stability and compatibility of antimicrobial lock solutions by BOOKSTAVER, P BRANDON, ROKAS, KRISTINA E. E, NORRIS, LEANN B, EDWARDS, JULIE M, SHERERTZ, ROBERT J

“…PURPOSEPublished stability and compatibility data on a growing array of solutions used for antimicrobial lock therapy (ALT) are reviewed. SUMMARYALT involves…”
Get full text

Hepatitis B Virus Reactivation: Risk Factors and Current Management Strategies by Smalls, Danielle J., Kiger, Reagan E., Norris, LeAnn B., Bennett, Charles L., Love, Bryan L.

“…Hepatitis B virus (HBV) is a global disease with significant morbidity and mortality. Worldwide, ~257 million people are chronically infected with HBV, defined…”
Get full text

Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: A report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project by Carson, Kenneth R., Newsome, Scott D., Kim, Ellen J., Wagner‐Johnston, Nina D., Geldern, Gloria, Moskowitz, Craig H., Moskowitz, Alison J., Rook, Alain H., Jalan, Pankaj, Loren, Alison W., Landsburg, Daniel, Coyne, Thomas, Tsai, Donald, Raisch, Dennis W., Norris, LeAnn B., Bookstaver, P. Brandon, Sartor, Oliver, Bennett, Charles L.

“…BACKGROUND Brentuximab vedotin (BV) is an anti‐CD30 monoclonal antibody‐drug conjugate that was approved in 2011 for the treatment of patients with anaplastic…”
Get full text

Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye's Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR) by BENNETT, Charles L, STARKO, Karen M, XIRASAGAR, Sudha, TRENERY, Alyssa, LOPEZ, Isaac, KAHN, Adam, MURDAY, Alanna, LUMINARI, Stefano, COURNOYER, Denis, LOCATELLI, Francesco, RAY, Paul, MATTISON, Donald R, THOMSEN, Henrik S, COWPER, Shawn, SARTOR, Oliver, MACDOUGALL, Lain C, QURESHI, Zaina P, BRANDON BOOKSTAVER, P, MILLER, April D, NORRIS, Leann B

Get full text

Reply to A.M. Zeidan et al by Bian, John, Norris, LeAnn B, Bennett, Charles L

Get full text

Regulatory and Clinical Experiences with Biosimilar Filgrastim in the U.S., the European Union, Japan, and Canada by Chen, Brian, Nagai, Sumimasa, Armitage, James O., Witherspoon, Bartlett, Nabhan, Chadi, Godwin, Ashley C., Yang, Y. Tony, Kommalapati, Anuhya, Tella, Sri Harsha, DeAngelis, Carlo, Raisch, Dennis W., Sartor, Oliver, Hrushesky, William J., Ray, Paul S., Yarnold, Paul R., Love, Bryan L., Norris, LeAnn B., Knopf, Kevin, Bobolts, Laura, Riente, Joshua, Luminari, Stefano, Kane, Robert C., Hoque, Shamia, Bennett, Charles L.

“…Biosimilar filgrastims are primarily indicated for chemotherapy‐induced neutropenia prevention. They are less expensive formulations of branded filgrastim, and…”
Get full text

Toxicity and costs of toxicity associated with new cancer drugs: international implications by Hermanson, Terhi, Norris, LeAnn B, Bian, John, Sartor, Oliver, Bennett, Charles L

Get full text

Progressive multi‐focal leucoencephalopathy among ibrutinib‐treated persons with chronic lymphocytic leukaemia by Bennett, Charles L., Berger, Joseph R., Sartor, Oliver, Carson, Kenneth R., Hrushesky, William J., Georgantopoulos, Peter, Raisch, Dennis W., Norris, LeAnn B., Armitage, James O.

Get full text

Assessing Pharmacy Residents' Knowledge of Biostatistics and Research Study Design by Bookstaver, P Brandon, Miller, April D, Felder, Tisha M, Tice, Danielle L, Norris, LeAnn B, Sutton, S Scott

“…BACKGROUND: Historically, clinicians have demonstrated a lack of confidence and poor aptitude for biostatistics as a tool for medical literature…”
Get full text

Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents: A Root Cause Analysis Using the "ANTICIPATE" Framework by Jacob, Sony, Nichols, Judy, Macdougall, Iain C, Qureshi, Zaina, Chen, Brian, Yang, Y Tony, Norris, LeAnn B, Bennett, Charles L

“…Unexpected serious adverse drug reactions (sADRs) affecting patients with chronic kidney disease (CKD) who received erythropoiesis-stimulating agents were…”
Get full text

Melanoma complicating treatment with natalizumab for multiple sclerosis: A report from the Southern Network on Adverse Reactions (SONAR) by Sabol, Rachel A., Noxon, Virginia, Sartor, Oliver, Berger, Joseph R., Qureshi, Zaina, Raisch, Dennis W., Norris, LeAnn B., Yarnold, Paul R., Georgantopoulos, Peter, Hrushesky, William J., Bobolts, Laura, Ray, Paul, Lebby, Akida, Kane, Robert C., Bennett, Charles L.

“…A 43‐year‐old female with multiple sclerosis developed urethral melanoma. The only potential risk factor was treatment with natalizumab, a humanized monoclonal…”
Get full text

Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease by Bennett, Charles L., Qureshi, Zaina P., Sartor, A. Oliver, Norris, LeAnn B., Murday, Alanna, Xirasagar, Sudha, Thomsen, Henrik S.

“…Background.In 2006, nephrologists in Denmark unexpectedly identified chronic kidney disease (CKD) patients with a new syndrome, nephrogenic systemic fibrosis…”
Get full text

Primary prophylaxis with hematopoietic colony stimulating factor: insights from a Canadian cost-effectiveness analysis by Strassels, Scott A, Dickson, Michael, Norris, Leann B, Bennett, Charles L

“…Strassels et al discuss the cost-effectiveness of primary prophylaxis with filgrastim or pegfilgrastim against febrile neutropenia in patients with diffuse…”
Get full text

Linking Drugs to Obscure Illnesses: Lessons from Pure Red Cell Aplasia, Nephrogenic Systemic Fibrosis, and Reye’s Syndrome. A Report From the Southern Network on Adverse Reactions (SONAR) by Bennett, Charles L., Starko, Karen M., Thomsen, Henrik S., Cowper, Shawn, Sartor, Oliver, Macdougall, Iain C., Qureshi, Zaina P., Bookstaver, P. Brandon, Miller, April D., Norris, LeAnn B., Xirasagar, Sudha, Trenery, Alyssa, Lopez, Isaac, Kahn, Adam, Murday, Alanna, Luminari, Stefano, Cournoyer, Denis, Locatelli, Francesco, Ray, Paul, Mattison, Donald R.

“…Identification of serious adverse drug reactions (sADRS) associated with commonly used drugs can elude detection for years. Reye’s syndrome (RS), nephrogenic…”
Get full text

Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication by Raisch, Dennis W, Campbell, Wesley, Garg, Vishvas, Qureshi, Zaina P, Bookstaver, P Brandon, Norris, LeAnn B, Bennett, Charles L

“…Anaphylactic reactions (ARs) have been frequently reported with taxanes. The authors' purpose was to summarize published case reports and describe ARs from…”
Get more information